Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia
2017 · Blood · 1,419 citations
https://doi.org/10.1182/blood-2017-04-779405
M
Mikkael A. Sekeres
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
1.4K
Papers
37.1K
Citations
91
h-index
395
i10-index
Mikkael A. Sekeres is an academic researcher from University of Miami. The author has contributed to research in topics: Acute Myeloid Leukemia Research & Myeloproliferative Neoplasms: Diagnosis and Treatment & Chronic Myeloid Leukemia Treatments. The author has an h-index of 91, co-authored 1233 publications.
ORCID: 0000-0003-2009-6524Papers by this author
worksRandomized phase 2 trial of pevonedistat plus azacitidine versus azacitidine for higher-risk MDS/CMML or low-blast AML
2021 · Leukemia · 109 citations
https://doi.org/10.1038/s41375-021-01125-4
Extended survival and reduced risk of AML progression in erythroid-responsive lenalidomide-treated patients with lower-risk del(5q) MDS
2013 · Leukemia · 98 citations
https://doi.org/10.1038/leu.2013.305
Special considerations in the management of adult patients with acute leukaemias and myeloid neoplasms in the COVID-19 era: recommendations from a panel of international experts
2020 · The Lancet Haematology · 86 citations
https://doi.org/10.1016/s2352-3026(20)30205-2
Therapy-related myelodysplastic syndromes deserve specific diagnostic sub-classification and risk-stratification—an approach to classification of patients with t-MDS
2020 · Leukemia · 73 citations
https://doi.org/10.1038/s41375-020-0917-7
Safety and Efficacy of AG-221, a Potent Inhibitor of Mutant IDH2 That Promotes Differentiation of Myeloid Cells in Patients with Advanced Hematologic Malignancies: Results of a Phase 1/2 Trial
2015 · Blood · 72 citations
https://doi.org/10.1182/blood.v126.23.323.323
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat